A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00162071|
Recruitment Status : Terminated (Sponsor decided not to continue with the development program)
First Posted : September 13, 2005
Last Update Posted : February 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease Ischemic Heart Disease||Drug: apadenoson||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||"A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration|
|Study Start Date :||July 2005|
|Actual Primary Completion Date :||March 2006|
- Measurements of Technetium Tc99m Sestamibi activity will be obtained from various regions of the body at the end of the study to determine optimal imaging times.
- A comparison of adverse events will be conducted at the end of the study to assess safety.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162071
|United States, New York|
|New York, New York, United States, 10025|
|Principal Investigator:||E Gordon DePuey, MD||St. Luke's-Roosevelt Hospital Center|